H1 2025 earnings

H1 2025 earnings

H1 2025 Pharma Earnings: Key Takeaways from Chinese and Global Players

H1 2025 earnings show Chinese pharma entering a new growth phase, led by oncology innovation, biologics, and international licensing deals. Global pharma maintains steady expansion via obesity, diabetes, and oncology blockbusters.